Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 4/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | CALCA | P06881 | 16/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599533 | 0.88 | CALCRL (1.00) | CALCRLCYP3A4CYP2D6CALCA | |
| SCHEMBL30543746 | 0.88 | CALCRL (1.00) | CALCRLCYP3A4CYP2D6CALCA | |
| SCHEMBL3594838 | 0.83 | CALCRL (0.74) | CALCRLCYP3A4CYP2D6CALCA | |
| SCHEMBL30231716 | 0.83 | CALCA (0.84) | CALCA | |
| SCHEMBL3604611 | 0.81 | CALCA (0.73) | CALCRLCYP3A4CYP2D6CALCA | |
| SCHEMBL30231971 | 0.81 | CALCRL (0.86) | CALCRLCYP3A4CYP2D6CALCA | |
| SCHEMBL5456743 | 0.81 | CALCRL (0.86) | CALCRLCYP3A4CYP2D6CALCA | |
| SCHEMBL3607829 | 0.80 | CALCRL (1.00) | CALCRLCYP3A4CYP2D6CALCA | |
| SCHEMBL13053544 | 0.80 | CALCRL (1.00) | CALCRLCYP3A4CYP2D6CALCA | |
| SCHEMBL13053295 | 0.80 | CALCRL (0.89) | CALCRLCYP3A4CYP2D6CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552906-B1 | CGRP RECEPTOR ANTAGONIST | BRISTOL MYERS SQUIBB CO (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8481546-B2 | CGRP receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120059017-A1 | CGRP Receptor Antagonist | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059017-A1 | CGRP Receptor Antagonist | CALCRL, PTGIR, CALCR | CALCRL 1/4885CYP3A4 3127/4885CYP2D6 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.